ClotCare: Blood Clots, Stroke, Heart Attack
Monday, July 22, 2024
Home   |   DVT/PE   |   Blood Clots   |   Coumadin/Warfarin   |   New Patients   |   Self Testing   |   Email List   |   Donate

Pick a Topic:

Find info on a:

We subscribe to the HONcode principles of the HON Foundation. Click to verify.
ClotCare complies with the HONcode standard for trustworthy health
verify here.

ClotCare is a member of the Coalition to Prevent Deep Vein Thrombosis (DVT Coalition)  ClotCare is a member organization of the Coalition to Prevent Deep Vein Thrombosis. Click here to learn more about the Coalition to Prevent Deep Vein Thrombosis and DVT Awareness Month, which is held each March.

FDA Recommends Dabigatran Approval
Agree with no ASA, still skeptical on RE LY vs new management options

Henry I. Bussey, Pharm.D.
September, 2010

Earlier this week, the FDA panel unanimously recommended that the FDA approve dabigatran. When posted this information, it drew a number of comments, which you can review at

I agree that data do not support the need to add aspirin in non-stented patients as long as INR is fairly well controlled. In ASPECT 2 and WARIS II, warfarin alone was at least as safe and effective as warfarin + ASA, and superior to ASA alone. Even in "valve" studies, the studies that showed benefit with ASA usually had poor INR control (below target about 50% of the time).

Data presented by Wallentin ( on the composite of major events suggest the 50% of warfarin-treated patients (individual time in range > 67% of the time) did better (5.3%/yr maj events) than either dagibatran arm (7%/yr maj events). But those with "poor" INR control (< 53% time in range) did much worse (11.9%/yr maj events)than those on dabigatran. Also the wide use of ASA in RE LY may have increased bleeding with warfarin while possibly blunting the questionable increase in MI with dabigatran (see Combining patient self-testing with online management (with any of 2 or 3 available sysems) can greatly improve efficiency of management and achieve time in range of about 80% overall. If we change our management model, then the most cost-effective and justifiable approach may be to use warfarin + self-testing for those whose INRs are easily controlled and embrace dabigatran as a welcomed alternative for those who have difficulty maintaining optimal INR control. But we must not forget the need to educate patients and monitor for both bleeding and adherence to the medication regimen regardless of medication selected since major bleeding remains a significant risk with either agent.

Ask a question about blood clots or anticoagulant medications Have questions? Ask ClotCare. Send questions by email to

ClotCare is a 501(c)(3) non-profit organization generously supported by your tax-deductible donations and grants from our industry supporters.

Blood Clot Activities Calendar

New Postings:

Click here to view full list of new postings
ClotCare Home | New Postings | Patient Postings | Clinician Postings | Join Our Email List | Useful Web Links
CE Opportunities | Training Programs | DVT & PE Stories | Editorial Board | Financial Support
About ClotCare | DVT Coalition | Donate to ClotCare | Contact Us
Key topics discussed on ClotCare include: Blood Clots | Deep Vein Thrombosis (DVT) | Pulmonary Embolism (PE) | Atrial Fibrillation (A. Fib or AF) | Heart Attack | Stroke | Transient Ischemic Attack (TIA) | Mini Stroke | Bleeding Complications | Vascular Surgery | Surgical Blood Clot Removal | Warfarin | Coumadin | Lovenox | Low Molecular Weight Heparin (LMWH) | Heparin | Anticoagulants | Plavix | Aspirin | Antiplatelets | Blood Thinners
Copyright 2000-2018 by ClotCare. All rights reserved.
Terms, Conditions, & Privacy | Image Copyright Information
19260 Stone Oak Parkway, Suite 101 | San Antonio, TX 78258 | 210-860-0487
Send comments to
Monday, July 22, 2024